Overview
Chronic arthritis following chikungunya virus (CHIKV) infection is a debilitating condition characterized by persistent joint pain and swelling, often persisting for months or years post-infection. It primarily affects individuals exposed to Aedes mosquitoes, particularly in tropical and subtropical regions. Given its significant impact on quality of life, including limitations in daily activities and employment, early recognition and management are crucial in day-to-day clinical practice to mitigate long-term disability and improve patient outcomes 13.Pathophysiology
The pathogenesis of chronic arthritis in CHIKV infection involves complex interactions between viral persistence, immune dysregulation, and tissue damage. Initially, CHIKV replicates within host cells, utilizing the host's cellular machinery to produce non-structural and structural proteins crucial for viral replication and assembly 1. The non-structural proteins, particularly nsP2, play a pivotal role in suppressing the host's interferon response, facilitating viral evasion of innate immunity 112. This immune evasion contributes to prolonged viral persistence, either through residual viral RNA or incomplete viral clearance, which sustains chronic inflammation 2.At the cellular level, persistent viral antigens trigger an ongoing immune response characterized by elevated levels of pro-inflammatory cytokines such as IL-6, IL-1β, TNF-α, and chemokines like MCP-1 and IP-10 25. These cytokines drive synovial inflammation and fibrosis, leading to joint damage and persistent arthralgia 27. Additionally, the persistence of the E1 glycoprotein within joint tissues has been implicated in sustaining chronic inflammation, further contributing to the chronicity of the arthritis 2.
Epidemiology
Chikungunya virus infections predominantly affect tropical and subtropical regions, with significant outbreaks reported in Africa, Asia, Europe, and the Americas since the early 2000s 13. The incidence varies widely depending on the region and mosquito vector prevalence. For instance, during major outbreaks like those in La Réunion (2005) and Italy (2007), the attack rates were high, affecting millions 3. Epidemiological studies indicate that while anyone can be infected, adults, particularly those over 30 years old, are more frequently affected and are at higher risk for developing chronic arthritis 34. Geographic risk factors include areas with dense Aedes mosquito populations, and no clear sex predilection has been consistently identified, though some studies suggest a slight female predominance 310.Clinical Presentation
Patients with chronic chikungunya arthritis typically present with persistent polyarthralgia and arthritis, often involving multiple joints, predominantly small joints of the hands and feet 23. Common symptoms include joint swelling, stiffness, particularly in the morning, and pain that can be debilitating. Atypical presentations may include involvement of larger joints or atypical patterns of joint involvement that can complicate diagnosis 2. Red-flag features include unexplained weight loss, fever, or signs of systemic involvement such as heart or neurological symptoms, which may suggest complications beyond localized joint disease 34.Diagnosis
The diagnosis of chronic arthritis following CHIKV infection involves a combination of clinical evaluation, serological testing, and sometimes imaging and synovial fluid analysis. Key diagnostic steps include:Management
First-Line Treatment
Second-Line Treatment
Refractory Cases
Contraindications:
Complications
Chronic chikungunya arthritis can lead to several complications:Prognosis & Follow-Up
The prognosis for chronic arthritis post-CHIKV infection varies, with some patients experiencing gradual improvement over months to years, while others face persistent symptoms. Prognostic indicators include the duration of symptoms post-infection, initial severity, and response to treatment 310. Regular follow-up every 3-6 months is recommended to monitor disease progression and adjust treatment as needed. Key monitoring parameters include clinical symptom assessment, inflammatory markers, and functional capacity evaluations 34.Special Populations
Pregnancy
Management in pregnant women requires careful consideration due to potential teratogenic effects of certain medications; consult rheumatology for tailored treatment plans 3.Pediatrics
Children with chronic arthritis post-CHIKV infection may present with milder symptoms but require close monitoring for growth and development impacts; DMARDs should be used cautiously 3.Elderly
Elderly patients often have comorbidities that complicate treatment; prioritize non-pharmacological interventions and closely monitor for drug interactions 3.Key Recommendations
References
1 Ma M, Li L, Sun H, Zhang X. Pathogenesis of Chronic Arthritis Due to Chikungunya Virus and Advances in Vaccine Development. Viruses 2026. link 2 Brito MSAG, Marchi MS, Perin MY, Côsso IDS, Bumlai RUM, Silva Júnior WVD et al.. Inflammation, fibrosis and E1 glycoprotein persistence in joint tissue of patients with post-Chikungunya chronic articular disease. Revista da Sociedade Brasileira de Medicina Tropical 2023. link 3 Amaral JK, Bilsborrow JB, Schoen RT. Brief report: the disability of chronic chikungunya arthritis. Clinical rheumatology 2019. link 4 Watson H, Del Valle-Mendoza J, Aguilar-Luis MA, Aquino-Ortega R, Silva-Caso W, Tarazona-Castro Y et al.. Global ultrasound synovitis scores reflect symptom severity and patient outcomes in chronic chikungunya disease. Rheumatology (Oxford, England) 2025. link 5 Chaaitanya IK, Muruganandam N, Sundaram SG, Kawalekar O, Sugunan AP, Manimunda SP et al.. Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. Viral immunology 2011. link